Precision BioSciences generates trailing twelve-month revenues of approximately $45 million. As a biotechnology enterprise relying heavily on collaborative development agreements, licensing fees, and milestone payments from major pharmaceutical partners, its top-line financial results fluctuate significantly year-over-year depending on the timing of milestone achievements across its proprietary ARCUS gene-editing development programs.